Epidermal Growth Factor Receptor (EGFR) Protein Overexpression Recruiting Phase 2 Trials for Cisplatin (DB00515)

IndicationStatusPhase
DBCOND0071358 (Epidermal Growth Factor Receptor (EGFR) Protein Overexpression)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02205047Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction AdenocarcinomaTreatment